HC Wainwright Issues Negative Estimate for DTIL Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Investment analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Precision BioSciences in a research note issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2025 earnings at ($0.38) EPS and FY2025 earnings at ($2.77) EPS.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings data on Thursday, May 15th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $5.00 million.

Precision BioSciences Stock Down 1.3%

DTIL opened at $4.58 on Friday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The firm has a 50 day moving average price of $4.98 and a 200-day moving average price of $5.39. Precision BioSciences has a twelve month low of $3.61 and a twelve month high of $13.32. The stock has a market capitalization of $48.32 million, a price-to-earnings ratio of 76.35 and a beta of 1.55.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Samalin Investment Counsel LLC purchased a new stake in Precision BioSciences during the fourth quarter valued at approximately $59,000. Commonwealth Equity Services LLC purchased a new stake in Precision BioSciences during the fourth quarter valued at approximately $48,000. Lynx1 Capital Management LP purchased a new stake in Precision BioSciences during the fourth quarter valued at approximately $2,919,000. Moloney Securities Asset Management LLC increased its holdings in Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after buying an additional 56,100 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Precision BioSciences by 36.2% during the fourth quarter. Renaissance Technologies LLC now owns 109,798 shares of the company’s stock valued at $418,000 after buying an additional 29,200 shares during the last quarter. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.